GlobeNewswire by notified

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook


PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.

“Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results.

Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and roadmap with our Generation Ipsen program, based on Environment, Patients, People, and Governance.

As a significantly more diversified business across our three therapeutic areas and a geographically well-balanced company, we now have many sustainable and attractive growth opportunities across our portfolio and pipeline to create long-term value for all of our stakeholders and investors.”

Strategic outlook 2027

  • Several current and potential near-term launches, including Onivyde® (irinotecan), Bylvay® (odevixibat), elafibranor and Sohonos® (palovarotene), complemented by many pipeline milestones over the mid term

  • A strengthened and diversified business: a combination of seven anticipated and current medicines, each with expected peak sales of at least €500m

  • A global footprint and strong portfolio opportunity in the U.S.

  • External innovation: active business-development focus providing a platform to drive sustainable pipeline growth

  • ESG roadmap: ambitious Generation Ipsen goals for positive change to achieve net-zero emissions by 2045 and foster Ipsen’s culture centered on patients and society

Financial outlook

  • Total-sales average growth of at least 7% per year for the period 2023-27 and at constant exchange rates

  • Core operating margin in 2027 of at least 32% of total sales

This outlook excludes the impact of any potential additional late-stage1 external-innovation opportunities. The priority for capital allocation remains focused on external-innovation transactions across the three therapeutic areas while maintaining net debt, including contingent liabilities, below 2.0 times EBITDA.

Today’s event will include the following participants:

  • David Loew, Chief Executive Officer
  • Aymeric Le Chatelier, Chief Financial Officer
  • Christelle Huguet, Head of R&D
  • Bartek Bednarz, Head of Global Product ​& Portfolio Strategy
  • Stewart Campbell, President, North America
  • Mari Scheiffele, President, International

Event details
Today’s event will start at 12.30pm GMT, 1.30pm CET in London, with attendance by invitation only. The event will be webcast live; all participants will have an opportunity to ask questions and can access webcast details here. A recording will be available on


About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit

Ipsen contacts


Craig Marks            +44 (0)7584 349 193

Nicolas Bogler         +33 6 52 19 98 92


Amy Wolf               +41 79 576 07 23

Ioana Piscociu        +33 6 69 09 12 96

Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on

1 Phase III clinical development or later.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Investeringsforeningen Great Dane – Indkaldelse til ordinær generalforsamling 202426.2.2024 10:54:25 CET | pressemeddelelse

Investeringsforeningen Great Dane indkalder til foreningens ordinære generalforsamling, der afholdes mandag den 11. marts 2024, kl. 9.00. Indkaldelsen med sted, dagsorden samt fuldstændige forslag er vedhæftet. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på tlf. 38 14 66 00. Med venlig hilsen Invest Administration A/S Niels Erik Eberhard Direktør Vedhæftet fil GD_Indkaldelse til GF 11.03.2024 Clean

Investeringsforeningen Great Dane – Prospekt26.2.2024 10:51:11 CET | pressemeddelelse

Opdateret prospekt for Investeringsforeningen Great Dane offentliggøres dags dato. Prospektet er opdateret med nøgletal for 2023. Herudover er der foretaget generelle præciseringer, heriblandt i afsnittet for henholdsvis administration og depot. Prospektet er vedhæftet og kan også findes på foreningens hjemmeside Eventuelle spørgsmål kan rettes til undertegnede på telefon 3814 6600. Med venlig hilsen Niels Erik Eberhard Direktør Vedhæftet fil GD_Prospekt februar 2024_clean Inkl. SFDR

Investeringsforeningen Great Dane – Årsrapport 202326.2.2024 10:49:56 CET | pressemeddelelse

Bestyrelsen har i dag behandlet og godkendt årsrapporten 2023 for Investeringsforeningen Great Dane. Årsrapporten er vedlagt og vil ligeledes kunne rekvireres fra foreningens hjemmeside Årsrapporten vil blive fremlagt til godkendelse på foreningens ordinære generalforsamling, der afholdes den 11. marts 2024. Henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør Vedhæftet fil Great Dane - Årsrapport 2023 inkl. SFDR

Sparinvest SICAV suspenderer handel med alle afdelinger26.2.2024 10:33:01 CET | pressemeddelelse

København, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Under henvisning til Nasdaq Copenhagens regler for udstedere af investeringsbeviser skal Sparinvest S.A. hermed på vegne af de berørte afdelinger i Sparinvest SICAV offentliggøre, at indberetning af indre værdier til Nasdaq Copenhagen er udeblevet p.g.a. tekniske problemer. Handel med de berørte afdelinger ønskes derfor midlertidigt suspenderet. Der er tale om følgende afdelinger: Fund NameISINOrder Book CodeEquitas EUR RLU0362354549SSIEEURREthical Global Value EUR RLU0362355355SSIEGVEURREuropean Value EUR RLU0264920413SSIEUVEURRGlobal Value EUR RLU0138501191SSIGVEURRSustainable Corporate Bonds IG EUR RLU0264925727SSIGLIGEURRLong Danish Bonds DKK RLU0138507396SSILDBDKKRBalance EUR RLU0650088072SSIBAEURRBalance DKK RLU0673458609SSIBDKKRProcedo EUR RLU0139792278SSIPEURRProcedo DKK RLU0686499277SSIPDKKRSecurus EUR RLU0139791205SSISEURRSecurus DKK RLU0686498972SSISDKKRGlobal Convertible Bonds EUR RLU1438960566SSIGCBEURRValue Bonds - Global Ethic

SHARE BUYBACK TRANSACTIONS26.2.2024 10:30:00 CET | Press release

COMPANY ANNOUNCEMENT no. 12 - 26 February 2024 On 9 February 2024, DFDS A/S (“DFDS”) announced the initiation of a share buyback programme to be executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014, and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). Under the programme, DFDS will repurchase own shares of up to DKK 431m during the period from 12 February 2024 to 31 December 2024. A maximum of 3,400,000 shares will be repurchased. These limits include shares purchased under the Safe Harbour rules as well as shares purchased from Lauritzen Fonden Holding ApS on a pro rata basis to the shares purchased in the programme under a separate agreement with DFDS outside the Safe Harbour Rules. Transactions 19-23 February The following transactions have been made under the share buyback programme from Monday 19 February 2024 to Friday 23 February 2024: Number of sharesAvg. purchase price (D

HiddenA line styled icon from Orion Icon Library.Eye